
Oncology NEWS International
- Oncology NEWS International Vol 15 No 4
- Volume 15
- Issue 4
Revlimid Combination Granted Priority Review for Myeloma
The FDA has given priority review status to Celgene Corporation's supplemental new drug application for lenalidomide (Revlimid) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
SUMMIT, New JerseyThe FDA has given priority review status to Celgene Corporation's supplemental new drug application for lenalidomide (Revlimid) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. In two large phase III trials in previously treated myeloma patients, North American Trial MM-009 and International Trial MM-010, the combination showed safety and efficacy. Revlimid, a derivative of thalidomide (Thalomid), is an immunomodulatory drug. It previously received FDA approval for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality.
Articles in this issue
almost 20 years ago
Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLCalmost 20 years ago
ONS Annual Congress Heralds Start of Oncology Nursing Monthalmost 20 years ago
All-Star Panel Spells Out Onc Promises, Problemsalmost 20 years ago
Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosisalmost 20 years ago
ODAC Says No to Gemzar for Ovarian Caalmost 20 years ago
Femara Effective Even After Years of No Therapyalmost 20 years ago
XMRV Retrovirus Found in Some Prostate Ca'salmost 20 years ago
Taxotere Wins FDA Approval for Advanced Gastric CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































